Gilead Sciences, Inc. — 2014 Form 10-K
Business context and reporting period. Gilead is a research-based biopharmaceutical company focused primarily on HIV and liver diseases, with oncology, cardiovascular and respiratory businesses. This annual report covers the fiscal year ended December 31, 2014; quarterly figures below identify the fourth quarter specifically. The filing was signed February 25, 2015.
Financial performance and liquidity
| Metric | 2014 | 2013 | Change / context |
|---|---|---|---|
| Total revenue | $24.890 billion | $11.202 billion | Up 122% |
| Product sales | $24.474 billion | $10.804 billion | Up 127% |
| Operating income | $15.265 billion | $4.524 billion | Operating margin approximately 61%, versus 40% |
| Net income attributable to Gilead | $12.101 billion | $3.075 billion | Up approximately 294% |
| Diluted EPS | $7.35 | $1.81 | Up approximately 306% |
| Product gross margin | 85% | 74% | Improved mainly from Sovaldi and Harvoni product mix |
| Operating cash flow | $12.818 billion | $3.105 billion | Capital expenditures were $557 million; operating cash flow less capex was approximately $12.261 billion |
| Cash, cash equivalents and marketable securities | $11.726 billion | $2.571 billion | At December 31 |
| Working capital | $11.953 billion | $590 million | At December 31 |
| Total debt, net | $12.404 billion | $6.636 billion | $483 million current and $11.921 billion long-term at year-end |
Revenue growth was led by HCV medicines Sovaldi ($10.283 billion) and Harvoni ($2.127 billion); combined sales were $12.410 billion. Antiviral sales totaled $22.791 billion, or 91% of revenue. U.S. product sales were $18.1 billion and European product sales were $5.1 billion. Gross-to-net deductions totaled $7.3 billion, equal to 23% of gross product sales.
Fourth-quarter 2014 revenue was $7.314 billion, compared with $3.120 billion in fourth-quarter 2013. Net income attributable to Gilead was $3.487 billion versus $791 million; diluted EPS was $2.18 versus $0.47.
Material changes and unusual items
- Sovaldi and Harvoni drove the step-change in revenue and margin; more than 170,000 patients worldwide had been treated with a sofosbuvir-based regimen since launch.
- R&D expense rose 35% to $2.854 billion, including $350 million of collaboration/acquisition-related expenses and a priority-review-voucher purchase, as well as higher clinical-study spending. SG&A rose 76% to $2.983 billion, reflecting business expansion and higher drug-fee expense.
- The company recorded approximately $590 million of branded prescription drug fees in 2014, versus $110 million in 2013 and $85 million in 2012. A change in IRS rules required recognition in 2014 of the 2014 fee of $460 million and the 2013 fee of $142 million; the fee is not tax deductible.
- Gilead issued $8.0 billion of senior unsecured notes during 2014 and repaid $2.3 billion of debt. It repurchased $5.3 billion of shares and paid $4.1 billion to settle warrants associated with its 2014 convertible notes. The company announced a quarterly dividend and a further $15 billion repurchase authorization in February 2015.
- The effective tax rate fell to 18.8% from 27.3%, principally reflecting foreign earnings taxed at lower rates and tax credits, partly offset by state taxes, the non-deductible drug fee and amortization of the sofosbuvir intangible.
Outlook, commentary and principal risks
Management expected 2015 net product sales to grow, but not at 2014’s exceptional rate. It cited broader access and additional launches of Sovaldi and Harvoni as potential drivers. Management expected R&D and SG&A expenses to increase, including investment in clinical programs and expansion of commercial infrastructure, particularly in Europe and Asia. No numeric 2015 revenue or earnings guidance is provided in the filing text.
- HCV pricing, access and competition: Management expected continued pricing pressure, discounts and rebates as public and private payers negotiate coverage; payer mix, patient treatment volumes, reimbursement and competing therapies could materially affect sales. A U.S. Senate Finance Committee inquiry into Sovaldi pricing was ongoing.
- Product and customer concentration: HCV and HIV medicines account for most sales. Three U.S. wholesalers represented approximately 87% of U.S. product sales and 63% of worldwide revenue combined, creating exposure to purchasing and channel-inventory fluctuations.
- Intellectual property and litigation: Multiple disputes involving sofosbuvir/Harvoni—including claims by Idenix, Merck and AbbVie—could entail substantial defense costs, royalties or restrictions if resolved adversely. The company said potential loss ranges could not be estimated.
- Manufacturing and regulation: The FDA had raised quality-system and testing observations at Gilead’s Foster City facility; remediation and regulatory review could affect product supply or approvals. Key antiviral raw materials are substantially sourced from China, and certain products depend on single or limited suppliers.
- Receivables and market exposure: Southern European accounts receivable were $504 million, including $157 million more than 120 days past due. Approximately 26% of product sales were outside the United States; currency movements and hedging outcomes may affect results.
- Pipeline and other risks: Clinical candidates may fail or be delayed; the filing noted that simtuzumab studies in several cancers showed no clinical benefit. Other significant risks include reimbursement and healthcare reforms, generic entry, patent challenges, safety findings and government investigations.
The independent auditor issued an unqualified opinion on the financial statements and internal control over financial reporting; management also concluded disclosure controls and internal controls were effective at year-end.
Important facts for investors to verify
- Whether HCV treatment volumes, payer access, net pricing and rebates support the expected 2015 growth, and how competition affects market share.
- Product-level revenue trends and channel inventory, especially given reliance on three U.S. wholesalers and the possibility of first-quarter inventory drawdown.
- Progress and outcomes of the sofosbuvir/Harvoni patent cases, including potential financial exposure and any effect on commercialization.
- FDA follow-up on manufacturing observations, supply capacity and any impact on marketed products or pending approvals.
- Collection of overdue Southern European receivables and the evolution of gross-to-net deductions and the branded prescription drug fee.
- Debt maturities, cash deployment, and whether the announced dividend and share-repurchase plans proceed as intended.